A carregar...
NCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia
The advent of imatinib has dramatically improved outcomes in patients with chronic myelogenous leukemia (CML). It has become the standard of care for all patients with newly diagnosed chronic-phase CML based on its successful induction of durable responses in most patients. However, its use is compl...
Na minha lista:
| Publicado no: | J Natl Compr Canc Netw |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4234100/ https://ncbi.nlm.nih.gov/pubmed/21335443 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|